GRFS - Grifols, S.A.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Grifols, S.A.

Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan Sant Cugat del Vallès
Barcelona 08174
Spain
34 93 571 05 00
http://www.grifols.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees18,300

Key Executives

NameTitlePayExercisedYear Born
Mr. Raimon Grifols RouraCo-Chief Exec. Officer & Exec. DirectorN/AN/A1964
Mr. Ramón Riera RocaCOO, Chief Commercial Officer & Exec. Director1.06MN/A1955
Mr. Tomás Dagá GelabertVice Sec. & External DirectorN/AN/A1956
Mr. Víctor Grifols DeuCo-CEO & Exec. DirectorN/AN/A1977
Mr. Alfredo Arroyo GuerraCFO & Corp. VPN/AN/A1958
Amounts are as of December 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Corporate Governance

Grifols, S.A.’s ISS Governance QualityScore as of July 1, 2018 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 7; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.